Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01195194
Other study ID # SIRES
Secondary ID 2007-002378-68
Status Completed
Phase Phase 4
First received April 19, 2010
Last updated February 24, 2014
Start date March 2008
Est. completion date June 2013

Study information

Verified date February 2014
Source Hospital Universitari de Bellvitge
Contact n/a
Is FDA regulated No
Health authority Spain: Spanish Agency of Medicines
Study type Interventional

Clinical Trial Summary

The objective is to assess if low pre-transplantation donor specific T-cell reactive patients measured by Enzyme-linked immunosorbent spot (ELISPOT)assay can be safely managed with Calcineurin inhibitor(CNI)-free Sirolimus(SRL)-based immunosuppression.


Description:

Non randomized, pilot, prospective, open-label trial.


Recruitment information / eligibility

Status Completed
Enrollment 61
Est. completion date June 2013
Est. primary completion date June 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Age of donor and recipient between 18 and 65 years.

2. End-stage renal disease and scheduled to receive a primary or secondary renal allograft from a cadaveric, a living-unrelated, or a living-related donor. Patients scheduled for a second transplant must have maintained their primary graft for at least 6 months after transplantation, with the exception of graft failure due to technical reasons.

3. Panel reactive antibody (PRA) = 20%, with negative standard cross-match.

4. Women of childbearing potential must have a negative serum pregnancy test before randomization.

5. Women of childbearing potential must agree to use a medically acceptable method of contraception throughout the treatment period and for 3 months following discontinuation of assigned treatment.

6. Signed and dated informed consent prior to transplantation.

Exclusion Criteria:

1. Multiple organ transplants

2. Recipients of adult or pediatric en bloc kidney transplants or dual transplantation or non-heart beating donors.

3. Evidence of active systemic or localized major infection.

4. Evidence of infiltrate, cavitation, or consolidation on chest x-ray obtained during the screening/baseline evaluation.

5. Use of any investigational drug or treatment up to 4 weeks prior to transplantation.

6. Treatment with voriconazole, ketoconazole, itraconazole, fluconazole, clotrimazole, astemizole, pimozide, terfenadine, erythromycin, clarithromycin, telithromycin, troleandomycin, rifampin, rifabutin, or St. John's Wort that is not discontinued prior to randomization.

7. Treatment with aminoglycosides, amphotericin B, cisplatin, cisapride, metoclopramide, cimetidine, bromocriptine, danazol, or other drugs associated with renal dysfunction that are not discontinued prior to randomization.

8. Subjects with a screening/baseline total white blood cell count < 2,000/mm3 or absolute neutrophil count (ANC) < 500, platelet count < 100,000/mm3.

9. Fasting triglycerides > 400 mg/dL (> 4.6 mmol/L) or fasting total cholesterol > 300 mg/dL (> 7.8 mmol/L) despite optimal lipid-lowering therapy.

10. History of malignancy within 2 years of enrollment (except for adequately treated basal cell or squamous cell carcinoma of the skin).

11. Auto-immune diseases inactive immunosuppressive treatment ( 3 months prior to inclusion).

12. Patient with psychiatric disorders that could be non-compliance for the treatment.

13. Non Caucasian patients.

14. Active peptic ulcers that could produce intestinal absorption disorders.

15. Subjects who are known to be human immunodeficiency virus(HIV) or hepatitis B virus (HBV) positive. Patients with hepatitis C virus (HCV) positive should be excluded if polymerase chain reaction (PCR) positive or transaminates values are =2 upper normal value (UNV).

16. Diabetic patients.

17. Body mass index higher than 30 Kg/m2.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Disorder Related to Renal Transplantation

Intervention

Drug:
PRE-TRANSPLANT (PRE=before)
All patients will start with Thymoglobulin 1 mg/kg before transplant followed by 0,5 mg/kg/d during the next 5 days (total accumulated 3,5 mg/kg). Steroids will be administered at 0,25 mg/kg/d until month 3rd, followed by 0,1 mg/kg/d thereafter. Mycophenolate Mofetil: Pre-transplant 2 grams iv. After transplantation 1g/12 hours, starting iv and changing to oral formulation as soon as patient starts with oral intake (targeting mycophenolic acid (MPA) C0h levels 2-5 µg/mL).

Locations

Country Name City State
Spain Nephrology Department. Hospital Vall d'Hebró Barcelona
Spain Nephrology Department. Hospital de Bellvitge L'Hospitalet de Llobregat Barcelone

Sponsors (2)

Lead Sponsor Collaborator
Josep M Grinyo Carlos III Health Institute

Country where clinical trial is conducted

Spain, 

References & Publications (3)

Bestard O, Crespo E, Stein M, Lúcia M, Roelen DL, de Vaal YJ, Hernandez-Fuentes MP, Chatenoud L, Wood KJ, Claas FH, Cruzado JM, Grinyó JM, Volk HD, Reinke P. Cross-validation of IFN-? Elispot assay for measuring alloreactive memory/effector T cell responses in renal transplant recipients. Am J Transplant. 2013 Jul;13(7):1880-90. doi: 10.1111/ajt.12285. Epub 2013 Jun 13. — View Citation

Bestard O, Cruzado JM, Lucia M, Crespo E, Casis L, Sawitzki B, Vogt K, Cantarell C, Torras J, Melilli E, Mast R, Martinez-Castelao A, Gomà M, Reinke P, Volk HD, Grinyó JM. Prospective assessment of antidonor cellular alloreactivity is a tool for guidance — View Citation

Bestard O, Cruzado JM, Mestre M, Caldés A, Bas J, Carrera M, Torras J, Rama I, Moreso F, Serón D, Grinyó JM. Achieving donor-specific hyporesponsiveness is associated with FOXP3+ regulatory T cell recruitment in human renal allograft infiltrates. J Immunol. 2007 Oct 1;179(7):4901-9. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of biopsy-confirmed acute rejection episodes To describe cumulative biopsy-confirmed acute rejection in both groups by intention to treat analysis. 6 months No
Secondary Percentage of steroid-sensitive acute rejection episodes To describe the percentage of steroid-sensitive acute rejections rejection in both groups by intention to treat analysis. 6 months No
Secondary Percentage of acute rejection episodes requiring treatment with antilymphocyte antibodies. To describe the need for antibody treatment in acute rejection episodes in both groups by intention to treat analysis. 6 months No
Secondary Renal function estimated by Modification of Diet in Renal Disease (MDRD) formula. To describe renal function measured by MDRD in both groups by intention to treat and "on therapy" analysis. 12 months No
Secondary Proteinuria measured in g/day To describe proteinuria in g/day in both groups by intention to treat analysis. 6 months No
Secondary Histology at month 6 protocol kidney allograft biopsy To describe histology at month 6 in both groups by intention to treat and "on therapy" analysis. 6 months No
Secondary Percentage of patients with negative ELISPOT To describe percentage of patients with negative ELISPOT in both groups by intention to treat and "on therapy" analysis. 6 months No
Secondary Percentage of patients in group A requiring CNI introduction. To describe the percentage of patients in group A requiring CNI introduction. 24 months No
Secondary Percentage of patients presenting adverse events requiring study withdrawal To describe adverse events in the whole group ("screening failure" plus "intention to treat") in both treatments groups. 24 months Yes
Secondary Percentage of biopsy-confirmed acute rejection episodes To describe cumulative biopsy-confirmed acute rejection in both groups by intention to treat analysis. 12 months No
Secondary Percentage of steroid-sensitive acute rejections rejection episodes To describe the percentage of steroid-sensitive acute rejections rejection in both groups by intention to treat analysis. 12 months No
Secondary Percentage of acute rejection episodes requiring treatment with antilymphocyte antibodies To describe the need for antibody treatment in acute rejection episodes in both groups by intention to treat analysis. 12 months No
Secondary Proteinuria measured in g/day To describe proteinuria in g/day in both groups by intention to treat analysis. 12 months No
Secondary Percentage of patients with negative ELISPOT To describe percentage of patients with negative ELISPOT in both groups by intention to treat and "on therapy" analysis. 12 months No
See also
  Status Clinical Trial Phase
Completed NCT02581436 - Testing Immunosuppression Threshold in Renal Allografts To Extend eGFR N/A
Terminated NCT01561404 - Effect of the Inhibition of the Mammalian Target of Rapamycin on Metabolism and Exercise Phase 4
Recruiting NCT02849899 - Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period Phase 3
Not yet recruiting NCT01289301 - Studying the Effect of Changing Immunosuppression in Case of Polyoma BK Virus Infection of the Renal Transplant Phase 4
Completed NCT00905957 - Transversus Abdominis Plane Block For Renal Transplant Recipients N/A
Active, not recruiting NCT02843867 - Orientation of the Lymphocyte Response to the Occurrence of Atherosclerotic Complications After Kidney Transplantation
Active, not recruiting NCT02751099 - Bone and Cardiovascular Disease After Kidney Transplant
Completed NCT01646099 - Sun Protection of Kidney Transplant Recipients N/A
Completed NCT01744067 - The Effects of Omega-3 Fatty Acids in Renal Transplantation Phase 4
Active, not recruiting NCT03935958 - Curcumin in Kidney Transplant Recipients N/A
Recruiting NCT02513602 - Osseointegrated Dental Implants in Kidney Transplanted Patients N/A
Completed NCT01844713 - Evaluation of Sun Protection Education for Kidney Transplant Recipients N/A
Recruiting NCT01550445 - Steroid Withdrawal Immunosuppression After Renal Transplantation Phase 4
Completed NCT02540395 - Prospective Donor Specific T Response Measurment for IS Minimization in de Novo Renal Transplantation N/A
Completed NCT00724022 - Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation Phase 4
Terminated NCT00167661 - Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation Phase 1/Phase 2
Completed NCT03968588 - Standard- Versus Reduced-dose Tacrolimus Combined With Generic Mycophenolate Mofetil in De Novo Renal Transplantation Phase 4
Recruiting NCT02515643 - Contribution of Renal Function to Endothelial Dysfunction in Living Kidney Donors and Transplant Recipients N/A
Completed NCT00455013 - A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation Phase 2
Recruiting NCT02843763 - Study of Specific CD4 Tumors Th1 Responses in Renal Transplant After Occurrence of Cancer N/A